Study of people with recessive dystrophic epidermolysis bullosa
Part of Genetic & congenital, Skin clinical trials.
This study looks at the medical features and needs of people who have recessive dystrophic epidermolysis bullosa (RDEB). It may help doctors better understand the condition and plan better care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with RDEB by your local dermatologist
- You are 7 years old or older
- Your health is stable enough to travel to Stanford University Medical Center
- You can attend study-related visits at Stanford
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at the immune system in people with recessive dystrophic epidermolysis bullosa (RDEB) and tests how placental stem cells affect immune cells in the lab. It aims to understand the disease better and explore potential treatments.
This study follows people with dystrophic epidermolysis bullosa (DEB) who get scrapes on the surface of their eye (corneal abrasions). It collects information to better understand how often and how severely these eye injuries happen.
This study looks at long-term outcomes for people with recessive dystrophic epidermolysis bullosa (RDEB) who were previously treated with EB-101. It may help doctors understand how the treatment affects patients over time.
This study follows patients who have already received a gene therapy treatment called prademagene zamikeracel for a severe skin condition called recessive dystrophic epidermolysis bullosa (RDEB). The goal is to track long-term safety and health outcomes after treatment.
This trial tests a gene therapy called BVEC to see if it can prevent squamous cell carcinoma (a type of skin cancer) from coming back in people with a severe form of epidermolysis bullosa (fragile skin). It is for adults who have had a confirmed SCC and are willing to use the gene therapy.
This trial tests if intravenous immunoglobulin (IV IgG) can help people with a form of epidermolysis bullosa who have antibodies against collagen VII. It may reduce blistering and improve wound healing.
Hear when a new Epidermolysis Bullosa Dystrophica trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.